相关临床试验
252
49 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1960
进行中（未招募）
13
5.2%
已完成
117
46.4%
Enrolling By Invitation
5
2.0%
尚未招募
31
12.3%
招募中
27
10.7%
终止
5
2.0%
Unknown
53
21.0%
撤回
1
0.4%
暂无批准数据
- EG Biomed US Inc., a licensing partner of YD Bio Limited, has achieved CAP accreditation for its CLIA-certified laboratory in Bothell, Washington, meeting the gold standard in laboratory quality assurance. - The accreditation strengthens EG BioMed's ability to deliver advanced laboratory-developed tests supporting YD Bio's pancreatic and breast cancer detection programs in the U.S. market. - EG BioMed's Chief R&D Officer presented novel circulating cell-free DNA biomarker findings for monitoring pancreatic cancer metastasis at the AACR conference in Boston. - The achievement positions YD Bio and EG BioMed to expand their diagnostic portfolio focusing on early cancer detection and monitoring capabilities.
- Far Eastern Memorial Hospital in New Taipei City administered Taiwan's first dose of Kisunla (donanemab), a new Alzheimer's drug that targets underlying disease causes rather than just symptoms. - The monoclonal antibody treatment, developed by Eli Lilly, was given to an 83-year-old woman and represents a breakthrough approach to reducing amyloid plaques in the brain. - Both Kisunla and Leqembi require 12-18 months of treatment to significantly reduce amyloid accumulation, with fewer than 100,000 of Taiwan's 350,000 dementia patients eligible for these therapies. - While promising, experts caution these drugs are not cures and require ongoing monitoring, with long-term effectiveness and side effects still under evaluation.
• SL Bio, a clinical-stage biomedical company developing cellular and gene therapies, has entered a definitive business combination agreement with Horizon Space Acquisition II Corp., with the combined entity to be listed on Nasdaq. • The company's proprietary platforms include next-generation immunotherapies such as Armed-T and Gamma Delta T cell technologies targeting blood cancers, pancreatic cancer, and brain cancer with improved safety and accessibility. • Beyond oncology, SL Bio is advancing regenerative applications using cow milk-derived exosomes and plant extracts for skin and hair care products, with established commercial distribution across Asia.
- Ludwig Cancer Research scientists developed PLT012, a humanized antibody that blocks the CD36 fat transporter to restore immune function in tumors that exploit fat metabolism for immune evasion. - Preclinical studies in hepatocellular carcinoma and colon cancer liver metastases demonstrated PLT012's effectiveness both as monotherapy and in combination with checkpoint inhibitors. - The FDA granted PLT012 orphan drug status, and the therapy showed promise in human tumor samples while demonstrating favorable safety profiles in animal models. - This metabolic immunotherapy approach could address a broad range of cancers with lipid-rich microenvironments that resist conventional checkpoint blockade therapies.
- Taipei Medical University and MSD Taiwan have signed a groundbreaking Memorandum of Understanding to collaborate across six key areas, marking the first large-scale alliance between a global pharmaceutical company and a medical university in Taiwan. - The partnership aims to enhance Taiwan's healthcare ecosystem through initiatives including business mentorship for startups, improved clinical trial capabilities, industry-oriented curricula, and real-world evidence projects. - A cornerstone of the collaboration is the establishment of an "Expedited New Drug Pathway" to streamline access to innovative therapeutics, particularly first-in-class pharmaceuticals tested within TMU's 3,000-bed healthcare system.
- Avance Clinical, a global Contract Research Organization, has signed Memorandums of Understanding with four premier Taiwanese medical institutions, strengthening its GlobalReady model for biotech companies. - The partnerships with Taichung Veterans General Hospital, Taipei Medical University, China Medical University Hospital, and Kaohsiung Medical University Chung-Ho Memorial Hospital provide US biotechs access to Taiwan's advanced healthcare infrastructure and diverse patient populations. - This strategic expansion leverages Taiwan's regulatory efficiency and clinical expertise, particularly in areas like CAR-T cell immunotherapy, to accelerate innovative treatment development for patients worldwide.
- A comprehensive analysis of National Health Interview Survey data reveals approximately 2.99 million US adults with asthma report cost-related medication non-adherence, despite declining trends over the past decade. - Patients experiencing cost-related non-adherence face significantly higher risks of asthma attacks (95% higher) and emergency room visits (63% higher) compared to adherent patients. - Demographics play a crucial role, with non-Hispanic Black patients (20.3%) and females (19.5%) showing higher rates of cost-related non-adherence, while adults over 60 demonstrate better medication adherence.
